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Cell Migration, Chimerism, and 
Graft Acceptance, With Particular 
Reference to the Liver 
• 
Thomas E. Starzlt MD, PhD, Anthony J. Demetrist MD, Massimo Trucco, MD, 
Noriko Murase, MD, Camillo Ricordi, MD 
Improvements in the prevention or control of rejection of 
the kidney and liver are largely interchangeable and then 
applicable with little modification to thoracic and other 
organs (see Chapter 50). The mechanism by which antire-
jection treatment permits any of these grafts to be ac-
cepted, however, has been an immunological enigma. I - 8 
We have proposed9-" that the exchange of migratory leu-
kocytes between the transplant and the recipient with 
consequent long-term cellular chimerism in both is the 
basis for acceptance of all whole organ allografts and xeno-
grafts (Fig 27 - 1). Although such chimerism was first dem-
onstrated as recently as mid-1992, the observations have 
increased our insight into transplantation immunology 
and have encouraged the development of alternative ther-
apeutic strategies. 
LOCAL (GRAFT) CHIMERISM 
The Liver 
The first unequivocal evidence that whole organ. gra~s in 
humans become genetic composites (local chlmensm) 
was obtained in 1969 with karyotyping techniques in fe-
male recipients of livers obtained from male cadaveric 
donors. These studies were done by K.A. Porter of St. 
Mary's Hospital and Medical School in Lo.ndon on ~lo­
grafts from the first long-surviving patients ~n the Umver-
sitv of Colorado liver series. 16. 17 Postoperatively, both the 
hepatocytes and the endothelium of the major blood ves-
sels of the grafts retained their donor sex, whereas the en-
tire macrophage system. including the Kupifer cells, w~ 
replaced with recipient female cells (identified. by theIr 
characteristic Barr bodies) within 100 days (FIg 27 - 2, 
middle). The assumption for many years was tha~ the 
com posite (chimeric) structure of the hepauc allograft was 
a special feature of this organ. 
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Other Organs 
The illusion of the uniqueness of the hepatic graft was dis-
pelled in 1991 with the demonstration, first in rat J?od71s18 
and then in human intestinal grafts,19 that the eplthehum 
and vascular endothelium remained donor specific, 
whereas lymphoid, dendritic, and other leukocytes were 
replaced by recipient cells in the la~ina propria, Peyer:s 
patches, and mesenteric nodes. As With the hver, the chi-
merism of the intestinal graft was made easy to demon-
strate because of its large constituency of lympho-
reticular cells, 
The suspicion that this transformation must be occur-
ring with other kinds of whole organ grafts was promptly 
confirmed with the kidney '2. 20 and with the thoracic 
organs.21 -23 
DISCOVERY OF SYSTEMIC CHIMERISM 
Circumstantial Evidence 
Twenty-two years passed between the discovery of the 
chimerism of the transplanted liver and that of the intes-
tine; during this period. several clinical reports noted the 
local chimerism in long-surviving human kidney al-
lografts2o• 24-26 and in subhuman primates.27 Throughout 
this time, the tacit or explicit assumption was that the cells 
departing the liver or kidney had been destroyed. ti~h the 
evidence that the local chimeric changes occurred In all 
kinds of grafts, the burning question became what hap-
pened to the donor cells that had disappeared .from the 
grafts. Much earlier circumstantial eVidence eXisted that 
donor leukocytes migrating from the engrafted organs 
were still present in the body; however. this evidence had 
been largely ignored, forgotten, or misinterpreted. 
Kidney Transplantation, The resu~ts of exhaustive skin 
test studies (tuberculin, histoplasmm, blastomycln, and 
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Figure 27 -1 The mutual 
exchange of migratory 
immunocytes from the graft and 
the recipient after organ 
transplantation under potent 
pharmacological 
immunosuppression. GVH - graft 
versus host; HVG = host versus 
graft. (Reprinted from Immunology 
Today, 14, Starzl TE, Oemetris AJ. 
Murase N. et aI. Donor cell 
chimerism pennitted by 
immunosuppressive drugs: A new 
view of organ transplantation. 
326-332, Copyright 1993. with 
kind permission from Elsevier 
Science Ltd, The Boulevard. 
Langford Lane, Kidlington, OXS 
1GB, UK.) 
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coccidioidin; and tests for mumps, candidiasis, and 
trichophytosis) in our early Colorado kidney recipients ' 
and their donors provided a clue to the fate of the replaced 
donor cells.28 but one that was considered implausible at 
the time. Preoperatively, skin test reactions of recipients 
were negative and those of donors were positive; postoper-
atively, 77% of the recipients had positive skin test results 
(Fig 27 - 3). When this did not occur (in the other 23%), it 
meant that the kidney transplantation had failed. It was 
speculated that the secondary acquisition of the positive 
skin test results was "caused by adoptive transfer of donor 
cellular immunity by leukocytes in the renal graft vascula-
ture and hilar lymphoid tissue."28 However, the implica-
Figure 27 - 2 Steps in the 
understanding of liver 
transplantation, Historical view 
(left), realization In 1969 that the 
liver graft became a genetic 
composite or chimera (middle). 
and proof in 1992 of systemic 
chimensm (right). (From Starzl TE, 
Demetris AJ. Trucco M, et aI. Cell 
migration and chimensm atter 
whole organ transplantation: The 
basis of graft acceptance. 
HepatolOgy 17:1127 -1152, 1993.) 
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tion that cells from the graft had migrated to recipient tis-
sues was considered untenable nearly 30 years ago because 
the kidney was then thOUght to be a leukocyte-poor organ. 
Consequently, the flash of potential insight faded, in spite 
of the fact that the "transfer factor" of Lawrence29 was 
suggested as a possible amplification device for the ostensi-
bly small number of donor cells. 
Li ver Transplantation. Clues to the development of sys-
temic chimerism were also ignored after liver replacement 
and were correctly interpreted only later. When the com-
posite structure of liver allografts was discovered in \969, 
the continued viable presence outside the liver of the de-
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DONOR 
Positive 
Skin Tests 
n=61 
RECIPIENT 
Negative 
Skin Tests 
parted donor cells was signaled by the appearance and 
maintenance in the recipient blood of new donor-specific 
immunoglobulin (Gm) types. 17, 30 Fifteen years later, emi-
grant cells from the graft were proposed to be the source of 
anti-red blood cell antibodies that developed in patients 
who were the recipients oflivers from donors with ABO 
nonidentity.31 Subsequently, Davies et al32 showed the ap-
pearance in liver recipients of new circulating, donor-spe-
cific class I antigens. and they attributed these antigens to 
synthesis by the graft hepatocytes rather than to migratory 
passenger leukocytes. However, because these molecules 
were known to come from bone marrow-derived macro-
phages, dendritic cells, or both,33-3s they presumably had 
the same donor origin as the additional Gm types and 
anti - red blood cell antibodies after the completion of cell 
migration to extrahepatic sites. 
Direct Evidence of Chimerism 
In 1993, Murase et aP6.37 showed with flow cytometry that 
the stromal leukocytes leaving the small bowel allografts 
in rat recipients treated with a short course ofFK506 mi-
grated in large numbers through vascular routes to widelv 
distributed host lymphoid tissues. This created a state of 
systemic mixed allogeneic chimerism for at least 45 days 
that was free of lethal or even detectable graft-versus-host 
disease (GVHD). except in strain combinations in which 
the Brown Norway (BN) rat was the recipient. J6 - 38 Be-
cause the circulating cells detectable with flow cytometry 
were not studied for more than 45 davs and because 
their number diminished throughout -this time, the 
ultimate fate of these cells remained in doubt during all 
of 1991. 
The next. and as it turned out decisive, step was to look 
for evidence of chimerism in human recipients ofk.idneys, 
RECIPIENT 
Positive 
Skin Tests 
n = 47 (77%) 
Figure 27 - 3 Transfer of positive 
skin test results from kidney 
donors to recipients in patients at 
the University of Colorado, 
1962 -1964.21 Although 
inexplicable at the time, these 
observations reflected adoptive 
transfer after cell migration, 
repopulation, and chimerism. 
(From Starzl TE, Demetris AJ, 
Trucco M, et aI. Cell migration and 
chimerism after whole organ 
transplantation: The basis of graft 
acceptance. Hepatology 17:1127-
1152, 1993.) 
livers, and other organs whose successful transplantation 
had been performed many months or years earlier. This 
required more sophisticated and sensitive techniques than 
had been previously used for this purpose. The search 
from April through July 1992 for chimeric cells in the tis-
sues of these whole organ recipients was made feasible by 
the distinctive features of two chromosomes. In females 
who had been given an organ from a male donor, the pres-
ence in recipient tissues (or blood) of cells with the Y chro-
mosome was considered unequivocal evidence of sys-
temic chimerism. Alternatively, probes were used that 
detected human leukocyte antigen (HLA) alleles of chro-
mosome 6. For study of either the Y chromosome or chro-
mosome 6, one or the other of two technologies, and usu-
ally both, were exploited.9- '4 
One of these technologies was cytostaining, which 
allows the location and morphological characterization of 
phenotypically distinct donor and recipient cells. The cy-
tostaining for the Y probe was accomplished by a fluores-
cence method after in situ hybridization (Fig 27 -4). The 
immunostaining for the HLA markers was done with indi-
rect immunofluorescence. an avidin-biotin-complex im-
munoperoxidase method. or both and used monoclonal 
antibodies to class I and class II antigen phenotypes 
present in the donor but not the recipient. 
The other technology was polymerase chain reaction. 
which distinguishes donor from recipient DNA.9- '4 In the 
polymerase chain reaction search for the Y chromosome, 
oligonucleotides specific for the satellite region of the Y 
chromosome centromere Y -A and for the sex-determin-
ing region of the Y chromosome were used as primers to 
determine the presence of male DNA in the female recipi-
ent tissues. The polymerase chain reaction tests for donor-
and recipient-specific HLA alleles of chromosome 6 were 
performed by preliminary generic amplification of the 
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Figure 27 -4 Studies of patient OT (othotopic transplant) 64. 19'h years after her liver replacement 
from a male donor. Fluorescence alter in situ hybridization with the DYZ1 probe for the Y chromosome 
was used to differentiate male from female cells. A. The allograft liver was used as a positive control. 
About 60% of hepatocytes and a few sinusoidal cells retained the donor genotype (arrow); the Y 
chromosome in the negative hepatocytes was likely excluded from the 2-,um-thick sectioning plane. 
The yellow cytoplasmic material is autofluorescence ( X 250). B. Oil immersion microscopy was used 
to illustrate the variety of signals obtained in the liver; these formed a beaded to reticular pattern. often 
at the penphery of the nucleus ( X 1000). C. Skin biopsy findings show that spindle-shaped stromal 
cells with a similar signal for the Y chromosome were sparsely distributed in the 0.5- to 1-cm slide 
sections ( X 1000). (A to C from Starzl TE. Demetris AJ. Trucco M. et a!. Cell migration and chimerism 
alter whole organ transplantation: The basis of graft acceptance. Hepatology 17:1127 -1152. 1993.) 
ORB gene. followed by allele-specific amplification and 
testing (Fig 27 - 5). 
Human Kidney Recipients. These patients included 
some who had participated in the skin test studies nearly 3 
decades before. By this time. they had become part of an 
elite group of forerunners bearing the longest contin-
uously surviving kidney grafts in the world.39 Of the five 
who were studied 27 - 29 years after transplantation. one 
had stopped immunosuppression 12 years earlier and the 
others were still taking azathioprine with or without pred-
nisone. The distinction of donor from recipient cells was 
feasible because all five patients had received HLA-
incompatible kidneys: in two cases, the kidneys had come 
from donors of the other sex. 
Low-level chimerism was found in the host tissues of all 
five of these kidney recipients. Biopsy specimens of the al-
lografts showed that the cells that departed from the trans-
plants were replaced by similar cells from the host. Thus. 
in addition to systemic chimerism, these patients were 
shown to have chimeric kidney grafts composed of cells 
with two different genomes. 12. 20 
Human Liver Recipients. As with the kidney recipients. 
most of the patients in a cohort of 25 liver recipients stud-
ied for chimerism were clinically well and fully immuno-
competent by conventional in vitro testing when they 
were studied between 2 and 22 years after transplantation 
under azathioprine- or cyclosporine-based immuno-
suppression. 14 
Donor cell chimerism was found with cytochemical or 
polymerase chain reaction techniques in all 25 patients in 
locations that included the skin. lymph nodes. hean. 
lungs, spleen. intestine. kidneys, bone marrow, and 
thymus. Chimeric cells were present in larger numbers at 
any given site than they were in the long-surviving kidney 
recipients being studied at the same time. 
--------------------- -------
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Figure 27 - 5 Detection of chimerism by molecular human 
leukocyte antigen (HLA) ctass II typing in various tissues after liver 
transplantation in a patient with type I Gaucher's disease. The 
illustration shows southern blot analysis of DR1-specific amplification 
of the DNA extracted from small bowel, skin, bone marrow, blood, 
and liver. The denaturated DNA present on the nylon membrane was 
hybridized to a radioactively labeled DR1 (donor)-specific 
oligonucleotide probe (7001). In the case of the liver, only 'Aoo of 
amplification product was used. C = negative control of the 
polymerase chain reaction amplification. (From Starzl TE, Demetris 
AJ. Trucco M, et al. Cell migration and chimerism after whole organ 
transplantation: The basis of graft acceptance. Hepatology 
17:1127-1152,1993.) 
CELL TRAFFIC AND SITES OF DONOR-RECIPIENT 
IMMUNOLOGICAL INTERACTIONS 
The early events leading to the chimeric state after liver 
transplantation have been studied in rats lS and mice,41 in-
cluding the pathways of passenger leukocyte dissemina-
tion. Within minutes or hours, these cells leave the liver 
and migrate to the spleen. lymph nodes. thymus. and 
probably bone marrow, where they are destroyed by rejec-
tion in most animal models except those that use mice as 
subjects. However, under temporary immunosuppression 
in rats (FK506 daily for 2 weeks), these mononuclear cells 
pause for about 2 weeks in the lymphoid organs but then 
break out and move secondarily to all recipient tissues1s 
(Fig 27 -6). Rat liver recipients treated in this way (for ex-
ample, Lewis [LEW] to BN) survive indefinitely without 
further treatment and retain their graft and systemic 
chimerism. 
Interestingly, cell migration and chimerism with per-
manent survival of the engrafted liver occur without any 
immunosuppression in some rat strain combinations; of 
these combinations, BN to LEW has been most com-
pletely studied,6 but graft survival occurs without treat-
Figure 27 -6 The dissemination of passenger leukocytes from the 
graft (rat liver in these experiments) to the central lymphoid organs; 
these leukocytes become ubiquitous after a brief pause. The events 
are Similar to those after successful bone marrow transplantation. 
ment in virtually all mouse strain combinations no matter 
how severe the histoincompatibility.41 These nonrejecting 
liver recipients in either species and those whose liver ac-
ceptance is induced with immunosuppression can receive 
skin, a kidney, or a heart from the original donor strain but 
no other strain (donor-specific nonreactivity). This kind 
of evidence has indicated that the heavy endowment of the 
liver with potentially migratory leukocytes is the basis for 
the well-known but previously inexplicable phenomenon 
of hepatic tolerogenicity. 
Hepatic Tolerogenicity 
Our hypothesis is that cell migration and repopulation is 
the central mechanism of acceptance of all whole organ 
graftS.9- 1S Although this is a generic process, there are 
quantitative differences between organs in the density of 
the potentially migratory dendritic cells. macrophages, 
and lymphoid collections (Fig 27 - 7). The heavy endow-
ment of the liver with the foregoing leukocyte lineages (in-
cluding Kupffer cells) is a particularly striking feature that 
invites further speculation about the role of these cells in 
the well-known tolerogenicity of this organ. 
The immunological advantage of the liver relative to 
other organs includes a greater ease of inducing the accep-
tance of liver allografts or xenografts either after a limited 
course ofimmunosuppression4. 6. 40. 42 or, in swine43-4s and 
some rat strain combinations,46, 47 with no treatment at all. 
In addition, the transplanted liver graft is relatively resis-
tant to the prefonned antigraft antibodies that cause hy-
peracute rejection of the kidney and heart.4I-$1 Another 
quality is the Iiver's unusual ability to induce a state of 
unresponsiveness to other tissues and organs transplanted 
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concomitantly or subsequently from the donor or donor 
strain46, 49, S2 and even to shield these organs from the hy-
peracute rejection caused by preformed allospeciiicsi or 
xenospecifics3 antidonor antibodies. In all of these cir-
cu~stancesI the liver can quickly transform the recipient 
enVIronment to one more favorable to all donor tissues 
including itself. All of these qualities of the liver are evi~ 
dent in practically every mouse strain combination, no 
matter what the degree ofhistoincompatibility.41 
The foregoing observations have been attributed to he-
patic tolerogenicity incorrectly, we believe, because the 
term implies that the hepatocytes are responsible. We have 
proposed that the crucial variable distinguishing the toler-
ogenicity of one organ graft from that of another under ef-
fective immunosuppression (or, in some animal models, 
with no treatment) is its leukocyte, not its parenchymal 
component.9- 15• 41 This is a reversal of the immunogenic 
role described classically for the passenger leukocytes. S4-67 
Thus, because of the dense constituency of these migra-
tory leukocytes, the liver is high on the favorable tolero-
genic list, with the lung and intestine following and the 
kidney and heart bringing up the rear (see Fig 27 - 7). Ex-
perimental studies showing the less striking tolerogenicity 
of the lymphoreticular-rich spleen,68-70 the intestine, 18 
and the lung71 , 72 are compatible with this generalization. 
Tolerogenicity of Leukocyte-Poor Organs 
By the end of 1992, it was appreciated that all whole organs 
underwent the same process of potential tolerance induc-
tion as did the liver, although the dynamics of organs other 
than the leukocyte-rich intestine were not as easy to 
study.18, 19.36, 37 However, the same kind of traffic, in the 
context of alloactivation and rejection rather than toleri-
zation. had been well worked out earlier with the so-called 
lymphoid-poor organs. which included the kidney. Stud-
ies in untreated animals have shown that the alloreaction 
starts in two general sites: peripherally in the graft and 
centrally in the recipient lymphoid tissues. 
In a complete study of untreated rat kidney recipients 
perfomled in 1981. Nemlander and associates73 demon-
strated extensive leukocyte migration. If the investigators 
had given one or two doses of cyclosporine in their kidney 
transplantation experiments (which were with an "easy" 
strain combination) and had followed the animals further, 
they almost certainly would have uncovered the events of 
cell migration and long-term repopulation that waited an-
other dozen years for exposure with the liver. IS Larsen et 
al74 found that donor dendritic cells from heterotopic car-
diac allografts were released into the circulation. where 
they eventually homed into the T cell areas of the recipient 
spleen. I n the spleen. the donor cells were found to initiate 
the proliferation of recipient cells. and vice versa. 73-77 This 
reaction might be thOUght ofas an in vivo mixed lympho-
cyte response; it epitomizes central allosensitization with 
potential tolerization. 
Allosensitization and tolerization presumably also 
occur within the graft. Forbes et al76 showed that clustering 
of recipient lymphocytes occurs around donor dendritic 
cells in the interstitium of heart grafts. within a few days 
after transplantation. The recipient lymphoid cells un-
dergo blastogenesis and proliferate within these clusters. 
Figure 27 - 7 The explanatiOn for the variable ability under 
immunosuppression to induce the acceptance and ultimately tolerance 
of different organs. We postulate that the dendritic leukocyte is the 
single most important, although not the only. tolerogenic cell. The 
tissue content of these potentially migratory cells is liver> intestine> 
lung> kidney and heart. (From Starzl TE. Demetris AJ. Trucco M, et 
aI. Cell migration and chimerism after whole organ transplantation: The 
basis of graft acceptance. Hepatology 17:1127 -1152. 1993.) 
Demetris et al have described analogous events in rat livers 
being rejected.7s 
In human recipients of kidney grafts78, 79 under cyclo-
sporine plus prednisone immunosuppression, Hayry and 
von Willebrand noted what appeared to be a bidirectional 
mixed lymphocyte response in needle aspiration biopsy 
specimens. When collected blast cells were studied with 
the Staphylococcus aureus assay and alloantibodies to 
nonshared donor and recipient allelic specificities, most of 
the blast cells in some cases were derived from the donor; 
alternatively, the response was split, "resembling a bidi-
rectional mixed lymphocyte reaction in vitro."78 
In these models, the difference from the experiments 
with liver transplantation appears to be quantitative 
rather than fundamental. With the smaller number of pas-
senger leukocytes, there is a greater tendency to allosensi-
tization and less tendency to tolerogenicity. Nevertheless, 
COrry et also and Russell et al81 showed that tolerance 
without drug induction could be induced by heart and kid-
ney transplantation between weakly major histocompati-
bility complex-incompatible strains of mouse recipients. 
FUNCTIONAL CONSEQUENCES OF MICROCHIMEAISM 
Questions have been raised regarding whether the low-
level chimerism found in our long-surviving patients and 
experimental animals is an irrelevant histopathological 
curiosity or a condition with immunological significance. 
Such questions appear naive in view of Russell's elegant 
formal proof of the association of chimerism with ac-
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quired tolerance as well as runt disease.82 However, the 
skepticism was generated by the small numbers of chi-
meric donor cells in the recipient tissues of the patients 
and animals in our studies. We have called this condition 
microchimerism. a term introduced in the literature in 
1974 by Liegeois et al,83 to describe a small proportion of 
chimeric cells in the recipient blood. The presence of mi-
crochimerism is far from insignificant; there is much evi-
dence that the cumulative effect of microchimeric cells is 
substantial, especially after liver transplantation, when 
they are most easily demonstrated. 
Metabolic Effects 
The small population of chimeric cells has been shown to 
affect total body metabolism in patients treated with liver 
transplantation for the enzyme deficiencies of type IV gly-
cogen storage disease and Gaucher's disease. In these dis-
eases, the consequences of the missing enzymes are wide-
spread storage of amylopectin and glucocerebroside, re-
spectively.11 The disorders were previously thought to be 
treatable only by bone marrow transplantation because 
the enzyme deficiency affects all cells; however, 2 - 8 years 
after liver replacement, there was a dramatic resorption of 
both kinds of storage material from host tissues (Fig 27-
8). As an explanation for the metabolic amelioration, chi-
meric donor cells were found to be ubiquitous in recipient 
tissues, including those of the heart, lymph nodes, bone 
marrow, intestine, and skin (see Fig 27 -5). There appar-
ently had been a coculture effect of a small number of chi-
meric donor cells on the contiguous, overwhelming num-
bers of enzyme-deficient recipient cells. 
The Immunological Interface 
The foregoing metabolic observations raised important 
questions about the potential cell-to-cell effects of other 
molecules directly involved in immunological rather than 
metabolic processes, including those subserving tolerance 
"{ 
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induction (see Fig 27 - 1). Perhaps such questions could 
be answered if it were known how the chimeric donor 
cells, many of which resemble dendritic cells, are perpetu-
ated for as long as 3 decades after transplantation. The 
dendritic cells and other leukocytes could be spawned by 
small numbers of pluripotent progenitor cells coming 
from the allograft interstitium. Dendritic cell precursors 
have been grown from mouse blood, bone marrow, or 
whole organs using media enriched with granulocytel 
macrophage colony - stimulating factor. 84 The products of 
these stem cells should reach terminal differentiation, 
however, unless there is a reason for their continued prolif-
eration. We have suggested that the subsequent survival 
and renewal of these cells depend on continuous mutual 
stimulation of the donor and recipient cell popula-
tions13• u in a process of tolerization that shares many of 
the cellular characteristics associated with immunity.ss 
CHANGED HOST AND GRAFT INTERACTIONS 
There are indirect ways to show that the coexisting im-
munocyte populations in successful cases (see Fig 27 - I) 
come to regard each other in a revised light. The evidence, 
on the one hand, is the fading of the threat of clinical rejec-
tion concomitant with development of donor-specific 
nonreactivity in spite of lightened treatment (or, in some 
animal models, without any treatment); on the other 
hand, the evidence is the waning specter of GVHD. It is 
quite natural to expect that the threat ofGVHD and rejec-
tion would decline contemporaneously in an organ recipi-
ent because both of the cell populations are receiving the 
same protective immunosuppression. Appreciation of the 
two-cell population relationship and the need not to alter it 
by ablating one side or the other was the crucial advance 
made empirically that permitted the successful engraft-
ment ofleukocyte-rich organs such as the liver, intestine, 
both together, or all of the intra-abdominal organs (multi-
visceral transplantation). 86 Once the cardinal principle 
was understood that low-level mixed allogeneic chimer-
Figure 27 - 8 A, An endOmyocardial biopsy specimen obtained in 1989, at the time of liver 
transplantation, revealed diffuse amytopectin deposits within and between cells. B, Another 
endomyocardial biopsy specimen obtained in 1992 revealed only traces of extracellular deposits 
(perIOdic aCid-Sdliff-O. X 100). (From Stanl TE. Demetria AJ, Trucco M. et al. Chimerism after liver 
transplantation for type IV glycogen storage and type I Gaucher's disease. Reprinted with permIssion 
from The New England Journal of MediCine, 328.745-749 and 1993.) 
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ism was invariably found after the successful transplanta-
tion of any whole organ, the reason GVHD was not com-
mon in liver, intestinal, or multivisceral recipients seemed 
obvious. Mixed chimerism was being produced empiri-
cally in the way that had been documented in the classic 
GVHD-free mouse bone marrow mixed chimerism 
models of Slavin et al87 and Ildstad and Sachs.88 
THE CRITICAL DENDRITIC CELL 
The generation of an immune response leading, under 
normal circumstances, to graft destruction, GVHD, or 
both, requires effective antigen presentation and recogni-
tion in its initial phase; this signal is followed by a second, 
costimulatory signal and the response of T cells to the 
combined signal.89 Both of these signals are normally de-
livered to T cells by professional antigen-presenting cells. 
Of these cells, the dendritic ce1l56- 58 (the most prominent 
chimeric cell by morphological criteria9- 15) is critical be-
cause it can modify the expression of cell interaction, 
major histocompatibility complex, and adhesion mole-
cules, all of which determine how antigen signals are 
heeded by T cells. 59 The dendritic leukocyte is thus the 
prime candidate in this tolerogenicity scenario, even 
though other lineages may also be essential for a successful 
outcome. 
Figure 27 - 9 The donor-recipient 
leukocyte interaction is a buffer against 
rejection on the one hand and graft-
versus-host disease on the other. Veto 
and suppressor cells are postulated to be 
the result of the interaction shown at the 
cell population interface. R. = iatrogenic 
immunosuppression. (Reprinted from 
Immunology Today, 14. Starzl TE. 
Demetris AJ, Murase N. et ai, Donor 
Match 
Partial 
Mismatch 
Total 
IMPACT ON TISSUE MATCHING 
In the directions of both host-versus-graft (HVG) and 
graft-versus-host (GVH) r~jectionI cellular .interactioD;s 
resulting in mutual natural ImmunosuppressIon are enVl-
sioned as occurring on a sliding scale with each further 
level of histoincompatibility (Fig 27 - 9). With effective 
immunosuppression, it has become increasingly possible 
throughout the last 3 decades to mitigate the alloreactions 
enough to allow the tolerogenic changes to occur after mu-
tual cell engagement and to allow a rapprochement to be 
reached between the coexisting immunocytes. The antici-
pated histocompatibili~ influence on both reje.ction and 
the severity of GVHD IS then expected to dwmdle. We 
have postulated9• 12-14 that this dwindling influence ex-
plains the poor correlation of HLA matching with out-
come after the cadaveric transplantation of whole organs, 
including the kidney.90-92 With regard to liver tra':lsplan-
tation, two large centers have actually reported. an mverse 
relationship between the quality ofHLA matching and the 
clinical outcome.93• 94 
RELATION OF CELL MIGRATION TO TOLERANCE 
The inadequacy of thymic clonal deletion to ex~lainK ac-
quired transplantation tolerance has been emphaslZed In a 
Mutual 
Natural 
Immunosuppression 
cell chimerism penmitted by 
immunosuppressive drugs: A new view of 
organ transplantation. 326-332. 
Copyright 1993. With kind penmission 
from Elsevier Science Ltd. The Boulevard. 
Langford Lane, Kidlington OX5 1GB, UK.) 
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1992 review.9s Although a discussion of the meaning of 
tolerance is beyond our intention, it should be noted that 
all of the mechanisms that explain clonal silencing, in-
cluding peripheral (nonthymic) clonal deletion and an-
ergy, could mesh with the discovery of the enduring graft-
host intimacy inherent with chimerism. The production 
of suppressor cells, veto cells, or both could be an epiphe-
nomenological consequence. Evidence of the long-term 
vitality and turnover of donor leukocytes in recipient tis-
sues is particularly supportive of the opinions of Ban de ira 
et al,8S Coutinho,96 and Cohen,91 who have defined ac-
quired tolerance as a high (not anergic) level of sustained 
immune activity in immunological networks. These net-
works presumably interact in a more complex way than do 
the idiotype systems originally postulated by Jerne.98 
Apart from explaining why the events of convalescence 
follow the same pattern after all transplantations, no mat-
ter what the organ, the cell migration -chimerism concept 
shows how donor-specific nonreactivity can be achieved 
with a common mechanism, regardless of the site of action 
of the immunosuppressive drugs administered, or, in 
some experimental models, without drugs at all. It has 
been proposed on the basis of observations in drug-free 
models of tolerance induction that T cell receptor occu-
pancy leads to the production of negative regulators of in-
terleukin (IL)-2 production (anergy proteins).89. 99 Ac-
cording to this hypothesis, during the course ofa normal T 
cell response (to alloantigens) these negative regulators of 
IL-2 production have an inconsequential effect because 
they are diluted by vigorous cell replication driven by IL-2. 
However, these negative regulators would accumulate 
with consequent anergy if clonal expansion were pre-
vented at any level (Fig 27 - 10), for instance. by the ab-
sence of a costimulatory signal in drug-free models. 89 
The same effect could be induced iatrogenically by 
pharmacological interdiction of IL-2 gene transcription 
(cyclosporine and FK506) or by the administration of a 
DNA synthesis inhibitor (azathioprine. cyclophospha-
mide. and numerous others). The use of monoclonal anti-
bodies that do not deplete T cells. such as those directed 
against the cell surface CD4 antigen, or monoclonal anti-
bodies that are directed against adhesion molecules, in-
cluding intercellular adhesion molecule 1 and lymphocyte 
function related antigen I (LF A-I), 100 can also be 
envisaged. 
However it occurs. the reciprocal educational process of 
donor and recipient leukocytes and its perpetuation re-
semble. in the direction of either rejection or GVHD (see 
Fig 27 - 10). the "infectious" transplantation tolerance of 
Waldmann and Cobbold. which can be passed on to naive 
lymphocytes and be self-sustaining in some circum-
stances. lOI It is postulated that in fully successful cases. the 
mmi-immune system of the graft is incorporated into the 
existing recipient immunological network. 13•IS a concept 
compatible with the hypothesis of Coutinho.96 
UNSTABLE MIXED CHIMERISM 
Cell migration conceptually reunites bone marrow trans-
plantation and whole organ transplantation. We believe 
that there are not different mechanisms involved in 
successful engrafiment and that these two seemingly dis-
------ HVG ... -----_ 
Functional Silencing 
APC 
f)" 
/ 'IL.2 
f~ ~ ~ ... ~KDKD ~ ~ I Anergyl 
0'0 ... 0 
IL·2 ( ++ Y 
r-c,P0 CY;;,c 
Mutual Natural 
Immunosuppression 
L-___ ~ GVHD ------.... 
Figure 27 -10 Model of dendritic cell antigen-presenting-cell-T cell 
interaction. showing the production within the nucleus of positive ( + ) 
and negative ( -) regulators (anergy proteins) of inter1eukin·2 (IL·2) 
gene transcription. In this model. anergy relates only to the IL-2 gene. 
and other cytokines (eg, interferon-y) may be secreted, albeit at 
suboptimal levels. In the absence of persistent costimulatory signals 
(or under the umbrella of immunosuppressive drugs). cell division does 
not proceed and negative nuclear regulators accumulate. resulting in T 
cell anergy, In addition to the action of immunosuppressive agents, 
chroniC antigen stimulation is envisaged as promoting anergy. In some 
instances, tolerance can be broken. for example. by administration of 
exogenous IL-2, HVG = host versus graft response (allograft 
rejection). (From Thomson. AW. Demetris AJ, Murase N. Starzl TE, 
Promotion of cell chimerism by immunosuppression drugs: A poSSible 
basiS for tolerance Induction following organ transplantation. In 
Thomson AW. Starzl TE. eds. Immunosuppressive Drugs: 
Developments in Anti-Rejection Therapy. London. Edward Arnold. 
1994, p 226. Reproduced by permission of Edward Arnold [Publishers] 
Umited.) 
parate clinical disciplines merely reflect contrasting 
treatment dogmas (Fig 27 - II). For bone marrow trans-
plantation. the conventional treatment strategy of recipi-
ent cytoablation eliminates mutual immunocyte engage-
ment and thus necessitates heavy reliance on HLA 
matching to prevent GVHD in the unbalanced system. 
The treatment of solid organ transplantation encourages, 
or at least permits. these consequences of mutual cell en-
gagement and thereby liberates the patient from the re-
strictions of HLA matching and from an overwhelming 
threat of GVHD. 
Failure of the chimeric and recipient immunocytes to 
reach an immunological truce (see Fig 27 -I) leads to re-
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Solid Organ Bone Marrow 
Figure 27 -11 The division of 
transplantation into two separate 
disciplines by divergent therapeutiC 
dogmas that created one-way versus 
two-way in vivo mixed lymphocyte 
response analogues. The policies used 
in bone marrow transplantation inhibited 
or preciuded bidirectional cell migration. 
whereas this phenomenon formed the 
fundamental basis of graft acceptance 
in whole organ transplantation. (From 
Starzl TE. Demetris AJ. Trucco M, et al. 
Cell migratiOn and chimerism after 
whole organ transplantation: The basis 
of graft acceptance. Hepatology 
17:1127 -1152. 1993.) 
.1 i I 
~y:f~ 
Non-essential : Tissue Match --KK;I;;KKKK;I;I--~ .. - Essential 
Acceptance ____ -~-"*"---- Graft Take ~l y~yyy .. Tolerance 
)) f~~ It 'l\\ 
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jection of the transplanted whole organ on the one hand, 
or to GVHD on the other; sometimes, it leads to both si-
multaneously. This phenomenon has been particularly 
well studied after intestinal transplantation between cer-
tain rat strain combinations involving the BN strain.36 - 38 
In ACt PVG. or LEW rats treated daily with variable 
doses ofFK506 for 14 days and weekly thereafter. success-
ful intestinal transplantation from fully allogeneic BN 
donors was not complicated by either rejection or fatal 
GVHD.38 In contrast, when the BN strain was the recipi-
ent. rejection of the ACI intestine was difficult to controL 
and when LEW or PVG intestine was transplanted. 
GVHD invariably developed after daily treatment was 
stopped. The two-way lymphocyte traffic from graft to 
host lymphoid organs and vice versa was similar with ei-
ther strain direction.36•37 Saat et al102 have described analo-
gous findings ofGVHD predisposition and rejection with 
the use of cyclosporine after WAG to BN rat intestinal 
transplantation but not BN to WAG. 
Further experiments in our laboratory have not clari-
fied why the BN rat is an easy donor but a difficult recipi-
ent. At a clinical level. the unresolved practical question is 
how to identify and avoid bad donor-recipient combina-
tions analogous to LEW, ACt or PVG to BN rats. particu-
larly when immunologically active organs such as the liver 
and intestine are engrafted. 
With human liver transplantation, preoccupation with 
rejection long obscured the fact that the GVH reaction, 
which is an incipient process and. in our opinion. a requi-
site for sustained engraftment in every case. can evolve to 
serious or fatal syndromes lO3 - 1 10 in the early postoperative 
-~r 
(Medawar) 
period. Clinically significant GVHD is observed in our 
liver program in approximately 5% of cases, manifesting 
as dermatitis.14 In the past, this dermatitis was usually at-
tributed to a self-limiting drug reaction or was considered 
an allergic manifestation. 
Although most of these patients can be treated success-
fully with increased immunosuppression (particularly 
prednisone), or occasionally by decreasing treatment. 
liver recipients with extensive skin involvement, gastroin-
testinal symptoms, and depression of the formed blood el-
ements have high mortality. lOS The chimerism that has 
been documented in such patients has differed only by 
being more extensive than that seen in patients who have a 
benign convalescence. 
The potential adverse consequences of deliberately un-
balancing the donor-recipient interface were illustrated by 
the case ofa 56-year-old man with gastric leiomyosarcoma 
and liver metastases who underwent a liver transplanta-
tion after an upper abdominal exenteration. 1 1 1 Just before 
the operation, the recipient was prepared with a single 
dose of 550-rad thoracoabdominal lymphoid irradiation 
followed by an intravenous dose of 19 X 109 non purged 
bone marrow cells. Several weeks postoperatively, he de-
veloped progressive and grave GVHD with more than 
80% skin involvement that did not respond to increased or 
decreased immunosuppression. On days 42 and 43 after 
surgery, respectively, 1.23 X 108 and 1.6 X 108 unpurged 
bone marrow cells per kilogram (collected and stored from 
before the preoperative total lymphoid irradiation) were 
infused intravenously. The rash dramatically resolved 
over the next 2 weeks. coincident with a taIl in mixed lin-
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eage donor cells in the blood from approximately 25% of 
total to 3% by flow cytometry, without the advent of 
rejection. 
The ability of the stored autologous marrow cells to tum 
off the potentially lethal GVHD may be a clue to the 
changes that occur during the mutual cell engagement of 
mixed chimerism. Although the cells used for rescue from 
GVHD were thought to be smaller in number than those 
in the circulation of the patient, they had not been exposed 
to donor marrow. Their therapeutic effect resembled the 
ability of virgin donor strain immunOcytes to "break toler-
ance," as originally described by Billingham et al. 112 
Two clinically relevant lessons from this traumatic ex-
perience have been reported elsewhere.HI The first was the 
inadvisability of trying to make space for the augmenting 
marrow cells with total lymphoid irradiation. The second 
lesson was the potential value of naive autologous bone 
marrow, which can be stored as a safety net should GVHD 
occur. These lessons have guided further attempts at bone 
marrow augmentation for the induction of tolerance in 
whole organ recipients. 
CLINICAL TRIALS OF BONE MARROW AUGMENTATION 
Kidney Alone or Kidney Plus Pancreatic Islets 
The concept developed in this chapter is that the content 
(and perhaps the specific lineages) of migratory cells, 
which are particularly numerous in the liver, confers po-
tential immunological advantages. These passenger leu-
kocytes, which are of bone marrow origin, have been 
considered an immunological liability for trans-
plantations"-67; however, under the appropriate condi-
tions, they may be tolerogenic, as exemplified by the liver. 
A corollary, therefore, is that organs such as the kidney 
and heart, which have a smaller leukocyte component, 
could be brought to the liver's tolerogenic potential. In 
fact, the frequently advanced strategy of intravenously in-
fusing donor bone marrow, donor blood (donor-specific 
transfusion), or other hematolymphoid cells at the same 
time or shortly after the transplantation of whole organs83, 
87,88, 113-116 is merely an augmentation of the normal post-
transplantation cell migration. To mimic the natural pro-
cess. these cells should be given perioperatively, not in ad-
vance or afterward, as has usually been done with the 
Monaco experimental model. 11"-116 
CLINICAL EXPERIENCE 
Since December 1992 at our center, four patients with 
end-stage renal disease have received a simultaneous 
kidney - bone marrow allograft from the same cadaveric 
donor. In addition, two diabetic (type I) renal patients 
were given pancreatic islets from their kidney-bone mar-
row donor. As a precaution. autologous bone marrow was 
harvested from all the recipients immediately before the 
kidney transplantation and cryopreserved for potential 
future use in case ofGVHD,111 as described in the preced-
ing section. 
The donor bone marrow was obtained from vertebral 
bodies atthe end of multiorgan procurement. and 3 X 108 
untreated bone marrow cells were infused intravenously 
immediately after the kidney transplantation. The two di-
abetic patients received the additional pancreatic islet in-
fusion intraportaIly at the time of the intravenous bone 
marrow infusion. All six patients were treated with FK506 
and prednisone. Chimerism was assessed in the recipients 
by flow cytometry, polymerase chain reaction, and im-
munostaining with peripheral blood lymphocytes. Immu-
nological monitoring was done by mixed lymphocyte re-
sponse and cell-mediated lympholysis. 
None of these patients exhibited GVHD. Detectable 
levels of donor cells were present in the peripheral blood 
lymphocytes of all six recipients during the 1- to 6-month 
follow-up. Donor cells were also detected in two patients 
whose lymph nodes were biopsied 2 and 4 months after 
transplantation. All six patients and their renal grafts are 
doing well. The two patients who were also given pancre-
atic islets have been treated too recently to evaluate their 
insulin status accurately. 
Further evaluation of passenger leukocyte augmenta-
tion (with bone marrow and other leukocyte sources) is of 
particular interest for pancreatic islet transplantation, 
which has consistently failed as a means of treating dia-
betes because of the high rate of rejection. I 17 Iritis possible 
to increase islet allograft survival with minimal ultimate 
immunosuppression by concomitant donor bone marrow 
infusion, this will be an approach opposite to the numer-
ous attempts to reduce islet immunogenicity by selective 
destruction of the antigen-presenting cells derived from 
bone marrow that are normally contained in islet prepara-
tions. 118 Donor bone marrow would then become a dose-
maneuverable component of any organ or cellular trans-
plantation for the facilitation of graft acceptance and for 
the induction of donor-specific nonreactivity. 
A LIVER TRANSPLANTATION ROAD MAP 
FOR DRUG WEANING 
As discussed earlier, past experience with conventional 
liver transplantation can be envisioned as a mini - bone 
marrow engraftment. In one reported group of 44 human 
liver recipients who had survived from 11 to 23 years, 6 
( 14%) had stopped all immunosuppression between 1 and 
11 years postoperatively and had subsequently experi-
enced clinically stable, drug-free intervals of 5 - 13 years; 
another 15 patients were drug free and stable after a 
shorter follow-up period. I ... 119 The most extreme example 
of early successful drug discontinuance in a liver recipient 
was after 6 months, with a subsequent follow-up period of 
3 years. A trial of drug weaning has been started in liver re-
cipients with a rejection-free course exceeding 5 years. 
Liver graft rejection (if it occurs) can be so effectively 
treated with FK506120 that the benefits of drug weaning 
appear to us to outweigh the risks in selected patients. 
This liver experience should provide insight regarding 
the use of bone marrow augmentation to achieve freedom 
from immunosuppression in recipients of organs and cells 
such as the kidney or pancreatic islets. Even when drug 
weaning has been decided upon, there is presently no way 
to know when a potential drug-free state has arrived. It 
seems clear that, if the clinical experience with the tolero-
genic livers is taken seriously, kidney or heart transplanta-
tion plus bone marrow augmentation will also require 
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protracted immunosuppression before the treatment can 
be stopped altogether and that, even then, it can be 
stopped only with precautions. Such conclusions have 
also been reached by Barber et al, 116 who used delayed sup-
plementary bone marrow for cadaveric kidney transplan-
tation as advocated by Monaco et al. 1I4• lIS 
Uver Transplantation 
CLINICAL EXPERIENCE 
Two liver recipients have received the same doses of peri-
operative bone marrow as patients in the kidney series, 
and 500-550 Gy total lymphoid irradiation was added 
preoperatively. The second patient developed nearly fatal 
G VHD from which he was rescued with stored autologous 
bone marrow (see under Unstable Mixed Chimerism). 
One year later, the patient underwent retransplantation 
for hepatitis C virus infection. The biopsy revealed pre-
dominantly hepatitis, but there were also signs of vascular 
rejection. Blood chimerism was no longer detectable im-
mediately before retransplantation, even by polymerase 
chain reaction. 
The unwise decision made regarding this patient and 
the second one to unbalance the donor-recipient interface 
iatrogenically with total lymphoid irradiation was based 
on the dogma that making space would facilitate engraft-
ment of the marrow. This concept has been eroded by di-
rect experimentation. 121. 122 The second patient, now 13 
months after surgery, has had a perfect clinical result since 
biopsy findings showed mild rejection at 2 weeks. She 
takes a daily dose of 6 mg of FK506 plus 5 mg of predni-
sone. There is evidence of chimerism in the peripheral 
blood lymphocytes by cytospin. 
Three additional patients underwent liver transplanta-
tion and bone marrow augmentation without total lymph-
oid irradiation. Their courses have been uncomplicated, 
with the exception of one episode of rejection 2 weeks after 
transplantation. All are blood chimeras. 
RISKS AND BENEFITS 
The augmentation in liver recipients of a process of cell 
migration and chimerism that is already highly opera-
tional after this kind of transplantation must be closely 
monitored for efficacy. Whether leukocyte augmentation 
will do more than could be achieved naturally in tolerance 
induction (with earlier achievement of a drug-free state) or 
will only increase the risk ofGVHD remains to be deter-
mined. The storage of autologous bone marrow for rescue 
should G VHD occur appears to be a mandatory precau-
tion in such trials. III 
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